Table 1 Demographics, clinical characteristics and task performance of participants.

From: Inefficient DMN Suppression in Schizophrenia Patients with Impaired Cognitive Function but not Patients with Preserved Cognitive Function

Demographics/clinical characteristics

 

Patients

Healthy participants n = 21 (10M:11F)

Preserved WM a n = 19 (8M:11F)

Impaired WM a n = 16 (11M:5F)

Mean ± SD

Mean ± SD

Mean ± SD

Age (years)

22.38 ± 3.94

24.84 ± 6.68

22.63 ± 6.71

Education (years)

13.33 ± 1.83

12.63 ± 2.11

12.19 ± 2.69

WAIS-Digital

70.63 ± 16.11

59.25 ± 12.00

WAIS-Information

18.82 ± 4.98

15.72 ± 4.03

Age at illness onset (years)

24.11 ± 6.63

22.94 ± 6.63

Duration of illness (months)

8.25 ± 5.69

8.38 ± 4.24

CPZ equivalents (mg)

234.22 ± 133.99

319.79 ± 287.02

SAPS total

19.95 ± 8.53

14.19 ± 11.98

SANS total

24.05 ± 24.50

38.44 ± 23.44

WM Performances

Mean ± SD

Mean ± SD

Mean ± SD

2-back target accuracy

79.05 ± 13.07

75.74 ± 14.78

42.69 ± 18.30

2-back non-target accuracy

90.14 ± 7.30

90.58 ± 8.39

66.88 ± 37.90

2-back target RT

619.64 ± 125.26

689.87 ± 121.94

729.34 ± 205.07

2-back non-target RT

631.56 ± 121.09

695.30 ± 128.38

733.02 ± 160.13

  1. Note:
  2. aDefined by performance on the 2-back memory task; WM, working memory; M, male; F, female; SD, standard deviation; WAIS-Digital, the Digit Symbol Subscale of Wechsler Adult Intelligence Scale; WAIS-Information, the information subscale of Wechsler Adult Intelligence Scale; CPZ, chlorpromazine; SAPS, Scale for Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms, RT, response time.